Track topics on Twitter Track topics that are important to you
MADRID — A conformational epitope-based assay may be effective in identifying systemic sclerosis patients whose disease is active, regardless of whether their condition is classified as limited or diffuse, according to a study presented at the EULAR Congress, here.“Currently, there is no single blood test or biomarker that can predict progression of systemic sclerosis,” presenter Gianluca Moroncini, MD, PhD, of Università Politecnica Marche, Ancona, Italy, said in a press conference. “Nobody can predict right now if Reynaud’s phenomenon is primary, or if it will evolve toward scleroderma or systemic sclerosis.”
Original Article: Epitope-based blood test may identify active systemic sclerosisNEXT ARTICLE
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity. This can be a drug or biochemical substance or a cell in an organism or organic sample. ...